For patients at high risk of cardiovascular events, PCSK9 inhibitors represent a critical advancement— especially when statins alone fail. But commercial success is challenged by real-world issues: high abandonment rates, low refill persistence, and costly drop-offs.

A leading pharmaceutical brand faced exactly this challenge. They turned to MedAdvisor Solutions to address one pivotal question: How can we drive measurable adherence in a complex, chronic therapy space with precisely targeted engagement?

 

For the full case study, click the "Download Now" button below.

 

Want to learn more about our unique individualized patient engagement solutions?

Contact Us